NxStage Medical CEO on Its Wall-Street-Beating Q4 Results
NxStage Medical founder & CEO Jeff Burbank tells MassDevice.com about its 4th-quarter and 2012 results, which topped Wall Street forecasts today, sending share prices up nearly 8% at their peak.
The Lawrence, Mass.-based medical device company said it pared its 4th-quarter losses by nearly 50%, to $2.4 million or 4¢ per share, on sales of $65.0 million for the 3 months ended Dec. 31, 2012. That amounts to top-line growth of 14.0% compared with Q4 2011.
For the full year, NxStage posted  losses of $14.6 million, or 26¢ per share, down 32.2% on sales of $242.1 million, up 11.5% compared with 2011.